Good morning, everyone, and nice to see you again after a long holiday break on this side of the pond. We hope the weekend respite, however long it lasted, was refreshing and reassuring. After all, that oh-so familiar routine of phone calls, Zoom meetings and lengthening to-do lists has returned with a vengeance. Such are the signs of progress, we hope. And so, we are also indulging in yet another part of our routine — the ritual cup of stimulation. Our choice today is maple bourbon. Please feel free to join us. Meanwhile, here are some tidbits. Good luck, today, and do keep in touch. …

A group of nine leading pharmaceutical and biotechnology companies pledged to only seek approval for Covid-19 vaccines demonstrated to be safe and effective, an apparent attempt to provide public reassurance despite the widely held view that the Covid-19 vaccine development process is politically tainted, STAT notes. In a statement, the companies pledged to “make the safety and well-being of vaccinated individuals our top priority.” Last week, the BIO trade group issued an open letter that made the same points.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy